close

ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Tumor-Activated Prodrug (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include IMGN242, a Phase I clinical trial product for the treatment of CanAg-expressing gastric, pancreatic, and colorectal cancer; and IMGN901, which is in three clinical trials for the treatment of multiple myeloma as well as other hematological malignancies, small-cell lung cancer, ovarian cancer, and other cancers of neuroendocrine origin. The company's products also include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; AVE9633, a Phase I clinical trial product for acute myeloid leukemia; AVE1642, a Phase I clinical trial product for the treatment of certain solid tumors and hematological malignancies; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkin's lymphoma; and BIIB015, a Phase I clinical trial product for the treatment of the treatment of solid tumors. It has collaborative partnerships with sanofi-aventis; Genentech, Inc.; Biogen Idec, Inc.; Biotest AG; Centocor, Inc.; Amgen, Inc.; Vernalis; and Cytovance Biologics LLC. ImmunoGen was founded in 1981 and is based in Waltham, Massachusetts.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	13.35
Volume	435154
Volume Avg	438835
52 Week High	16.20
52 Week Low	8.31
PE	N/A
PE (group average)	39
EPS Year	-0.87
EPS change Q/Q	-4.76%
EPS change Q/Q Yr ago	-4.76%
EPS change Q/Q next Q est	-21.43%
EPS change Y/Y	-4.82%
REV change Q/Q	23.81%
REV change Q/Q Yr ago	57.58%
EPS next Q est	-0.28
EPS next Y est	-0.68
Divident Annual	0.00
Dividend Yield	0%